![]() |
|
![]() |
|
Names | |
---|---|
IUPAC name
Methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate
|
|
Identifiers | |
3D model (JSmol)
|
|
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.163.930 |
PubChem CID
|
|
|
|
|
|
Properties | |
C16H15F3N2O4 | |
Molar mass | 356.30 g·mol−1 |
Insoluble | |
Solubility in other solvents | DMSO: 184 mg/mL; methanol and ethanol: 63 mg/mL |
Hazards | |
EU classification (DSD) (outdated)
|
Xi |
R-phrases (outdated) | R36/38 |
S-phrases (outdated) | S26 S36 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
![]() ![]() ![]() |
|
Infobox references | |
Bay K8644 is a chemical compound that functions as a calcium channel agonist. Bay K8644 is used primarily as a biochemical research tool for this effect. It is a structural analog of nifedipine with positive inotropic activity, and as an aromatic it is highly lipid soluble.
Bay K8644 targets Voltage-sensitive dihydropyridine (DHP) Calcium Channels (L-Type). It is the first positive inotropic agent shown to act specifically and directly on calcium channels.